Use this format when the original full-length article was published in JBJS.
Length limit: 2500 words, excluding references and figures.
Follow-up intervals: No less than 5 years since the previous publication and preferably at 5 or 10-year intervals, as long as no interim changes have occurred that require expedited reporting.
State, in a maximum of 150 words, why you are reporting the results at this interval and your major finding(s).
Briefly summarize and cite the original study published in JBJS. Describe the original:
- patient cohort
- data acquisition (prospective or retrospective)
- type of arthroplasty and critical aspects of surgical and cementing or cementless techniques
- type of series (selected or unselected, consecutive or not, by a single surgeon or multiple surgeons, at one or multiple institutions?)
List, but do not describe, the methods used to assess clinical and radiographic results, and cite the appropriate reference.
For reporting clinical results:
- use the same assessment scheme employed in your previous report
- include WOMAC scores for the current cohort
- use the clinical and radiographic nomenclature described by Johnston et al. (J Bone Joint Surg Am. 1990;72:161-8) for other pertinent data
- perform survivorship analyses (with calculation of confidence limits) using end points that are appropriate to your cohort
The results should include:
- the original number of patients/joints studied and the number of patients/joints studied since the last report
- the number of patients/joints who died, the number who were lost to follow-up, and the number currently being studied
- the number of patients/joints in the updated series who were examined, the number who responded to questionnaires, and the number with available radiographs
- the number of patients/joints in whom the primary joint replacement is still intact
- basic demographic characteristics of the cohort, especially any that might affect results (age, diagnosis, sex, height, weight, and level of activity)
- the number of arthroplasties revised for any reason; if the revised arthroplasties are included in the current series, report the status in this group separately
- complications since the last report, including infection, dislocation, breakage, osteolysis, wear, and so on
For survivorship analysis, the following end points should be used:
- revision for any causes
- revision for aseptic loosening of each/any component
- radiographic evidence of loosening of any component in patients who have not yet undergone revision arthroplasty
The conclusions should include:
- major factors limiting the longevity of the prosthesis at the time of this follow-up
- recommendations regarding the continued use of the prosthesis if it is still available
- if the prosthesis is not still available, lessons applicable to the current successor or to similar designs